|
Video: What is a Stock Split?
|
|
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. Co. has built its proprietary FUSION System discovery platform to develop a pipeline of covalent small molecule product candidates. Co.'s product candidate, BMF-219, is designed to be an orally bioavailable, selective irreversible covalent inhibitor of menin, a scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. According to our BMEA split history records, Biomea Fusion has had 0 splits. | |
|
Biomea Fusion (BMEA) has 0 splits in our BMEA split history database.
Looking at the BMEA split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Biomea Fusion shares, starting with a $10,000 purchase of BMEA, presented on a split-history-adjusted basis factoring in the complete BMEA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/19/2021 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$17.00 |
|
End price/share: |
$14.95 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-12.06% |
|
Average Annual Total Return: |
-4.27% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$8,794.97 |
|
Years: |
2.94 |
|
|
|
|
|